All In Biotech

Drug Trial Radar · NCT03092856

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

62

Actual

Start

Jul 19, 2017

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
University of Southern CaliforniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Mar 28, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body. Biological therapies, such as anti-OX40 antibody PF-04518600, use substances made from living organisms that may may stimulate the immune system in different ways and stop tumor cells from growing. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving axitinib with or without anti-OX40 antibody PF-04518600 may work better in treating patients with kidney cancer.

Conditions

  • Clear Cell Renal Cell Carcinoma
  • Metastatic Renal Cell Cancer
  • Recurrent Renal Cell Carcinoma
  • Stage IV Renal Cell Cancer

Interventions

  • Anti-OX40 Antibody PF-04518600Biological

    Given IV

  • AxitinibDrug

    Given PO

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • PlaceboOther

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Time from randomization until the earliest of documented disease progression (confirmed progression of disease) or death, assessed for up to 180 days

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Los Angeles County-USC Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • USC Norris Oncology/Hematology-Newport Beach

    Newport Beach, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • Weill Cornell Medical College, New York- Presbyterian Hospital

    New York, New York

  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

    Cleveland, Ohio

  • University of Pittsburgh Cancer Institute (UPCI)

    Pittsburgh, Pennsylvania

  • University of Virginia Cancer Center

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.